---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-171091"
form_type: "8-K"
ticker: "ALLO"
cik: "0001737287"
company_name: "Allogene Therapeutics, Inc."
filed_at: "2025-08-01T23:59:59+00:00"
generated_at: "2026-05-17T21:53:00.629940+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Allogene drops ALLO-647 after Grade 5 death; pivots to Dagger platform

## Summary
- Grade 5 hepatic failure from adenovirus attributed to ALLO-647; FC+ALLO-647 arm closed in ALPHA3 study.
- ALLO-647 removed from all ongoing and pipeline programs; no trial includes it.
- ALPHA3 proceeds as randomized trial of cema-cel with standard FC vs observation.
- Futility analysis on MRD conversion expected in first half 2026.
- Over 50 clinical sites activated; next-gen AlloCAR T uses Dagger Platform to reduce lymphodepletion.

## SEC filing metadata
- accession: 0001193125-25-171091
- form_type: 8-K
- ticker: ALLO
- cik: 0001737287
- company_name: Allogene Therapeutics, Inc.
- filed_at: 2025-08-01T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737287/000119312525171091/0001193125-25-171091-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737287/000119312525171091/d75167d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-171091
- JSON: https://secwatch.observer/filing/0001193125-25-171091.json
- Plain text: https://secwatch.observer/filing/0001193125-25-171091.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.